CompletedPhase 4NCT04077515
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
Studying Kaposiform hemangioendothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital of Fudan University
- Principal Investigator
- Kai Li, MD, PhD, MSW, LICSWChildren's Hospital of Fudan University
- Intervention
- Sirolimus(0.8mg/m2)(drug)
- Enrollment
- 92 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2019 – 2022
Study locations (1)
- Children's Hospital of Fudan University, Shanghai, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04077515 on ClinicalTrials.govOther trials for Kaposiform hemangioendothelioma
Additional recruiting or active studies for the same condition.